Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

The glucagon-like peptides: a double-edged therapeutic sword?

By Perry T.   Greig N.H.  

Trends in Pharmacological Sciences, Vol. 24, Iss. 7, 2003-07 ,pp. : 377-383

Elsevier

Access to resources Recommend Favorite

Glucagon as a target for the treatment of Type 2 diabetes

By Sloop Kyle W   Michael M Dodson   Moyers Julie S  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. : 593-600

Informa Healthcare

Access to resources Recommend Favorite

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

By Bak Ann Mosegaard   Egefjord Lærke   Gejl Michael   Steffensen Charlotte   Stecher Chalotte Willemann   Smidt Kamille   Brock Birgitte   Rungby Jørgen  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 10, 2011-10 ,pp. : 1153-1162

Informa Healthcare

Access to resources Recommend Favorite

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

By  

Current Pharmaceutical Design, Vol. 17, Iss. 38, 2011-01 ,pp. : 4379-4385

Bentham Science Publishers

Access to resources Recommend Favorite